1. S67 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a phase 3 randomized, controlled trial (EXPAND). (December 2018) Authors: Chuang, C-C; Rizio, AA; Loop, B; Lekstrom-Himes, J; You, X; Kosinski, M; Rendas-Baum, R; Davies, JC; Rowe, SM; Yang, Y Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S68 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis homozygous for F508del-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial (EVOLVE). (December 2018) Authors: Yang, Y; Rizio, AA; Chuang, C-C; Loop, B; You, X; Kosinski, M; Rendas-Baum, R; Lekstrom-Himes, J; Taylor-Cousar, J; Sole, A; Elborn, JS Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗